Sarepta Therapeutics opened lower at $16.44, compared with its previous close of $16.68. In the last trading session, the stock traded between $16.01 and $16.63. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Sarepta Therapeutics is now worth
$ 18.59
Resulting in a loss of
$ 81.41 (81.41%)
Note: Past profits do not guarantee future returns.
Rating from 17 Analysts
Today's Change
$-0.67 (-4.02%)
Day High
$16.63
Day Low
$16.01
Day Open
$16.44
Prev Close
$16.68
Volume
12,38,645
1W Return
-15.71%
1M Return
-8.26%
3M Return
-12.19%
6M Return
-17.48%
1Y Return
-10.96%
Market Cap ($ Mn)
1,717
PE Ratio
-
PB Ratio
1.44
PEG Ratio
-
ROE
-54.97%
ROCE
-25.62%
EPS (TTM)
$-0.27
1 Week
-15.71%
1 Month
-8.26%
3 Months
-12.19%
6 Months
-17.48%
9 Months
-10.86%
RBC Capital raises Sarepta Therapeutics price target to $18
RBC Capital raised Sarepta Therapeutics' price target from $17 to $18. Analyst Brian Abrahams maintained a Sector Perform rating. The price target increase represents a $1 adjustment.
6 days agoSarepta Therapeutics Q3FY26 Results: Revenue $324M, guidance raised to $1.3B
Total net product revenue reached $324 million in Q3FY26. PMO franchise contributed $240 million, while Elevidys generated $83 million. FY26 total net product revenue guidance raised to $1.25-$1.3 billion. Multiple ascending dose data for DM1 and FSHD expected in coming weeks.
7 days agoKSF launches probe into Sarepta Therapeutics over Elevidys safety claims
Kahn Swick & Foti launched an investigation into Sarepta Therapeutics' officers and directors. Probe focuses on alleged breaches of fiduciary duty regarding Elevidys safety disclosures. Three patient deaths from acute liver failure were reported between March and July 2025. Securities class action lawsuit alleging non-disclosure of material information is ongoing.
1mo agoHC Wainwright reiterates Sell on Sarepta Therapeutics, keeps $5 target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a Sell rating. The firm maintained a $5 price target for Sarepta Therapeutics. No changes were made to the previous investment recommendation.
1mo agoSarepta stock drops 8% as Novartis misses DM1 Phase 3 endpoint
Sarepta shares fell 8.09% to $20.68 after Novartis missed its primary Phase 3 endpoint for DM1 drug del-desiran. Novartis' HARBOR study failed to show statistically significant improvement vs placebo on video hand opening time. Sarepta's SRP-1003 Phase 1/2 data is expected in the second half of 2026. Technical analysis shows stock trading above 20-day and 50-day SMAs with RSI at 59.97.
2mo agoSarepta Therapeutics to present at Morgan Stanley healthcare conference
Sarepta Therapeutics senior management to speak at Morgan Stanley conference. Fireside chat scheduled for September 14 at 8:30 am ET. Live webcast available on company investor relations site. Session focuses on precision genetic medicine for rare diseases.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Sarepta Therapeutics is now worth
$ 18.59
Resulting in a loss of
$ 81.41 (81.41%)
Note: Past profits do not guarantee future returns.
